Zimmer Biomet (ZBH)
(Delayed Data from NYSE)
$113.34 USD
-0.03 (-0.03%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $113.50 +0.16 (0.14%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Price, Consensus and EPS Surprise
ZBH 113.34 -0.03(-0.03%)
Will ZBH be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ZBH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ZBH
Zimmer Biomet (ZBH) Procedure Recovery Aids Amid Macro Woes
Zimmer Biomet (ZBH) Unlocks Growth Plan for Future Success
ZBH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?
Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?
Here's Why You Should Retain Zimmer Biomet (ZBH) Stock for Now
Other News for ZBH
Zimmer Biomet to Present at the Goldman Sachs 45th Annual Healthcare Conference
Sell ideas in Staples and Health Care - Oppenheimer
Johnson & Johnson ties up acquisition of Shockwave Medical
Zimmer Biomet Holdings (ZBH) Receives a Buy from Piper Sandler
Zimmer Biomet price target lowered by $5 at Barclays, here's why